Our data argue for the development of more specific STAT5 inhibitors for EGFRvIII+ GBM or the identification of an alternative pharmacologic approach to inhibit the EGFRvIII-STAT5 signaling axis. This evidence concerns the gene STAT5A and glioblastoma.